Cargando…

The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran

BACKGROUND: Venous thromboembolism (VTE) is one of the main causes of mortality in patients with cancer. This study was conducted to assess the incidence of deep vein thrombosis (DVT) in breast cancer patients receiving outpatient cancer therapy. MATERIALS AND METHODS: This multi-center prospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharif-Kashani, Babak, Ghanbari Motlagh, Ali, Mafi, Ahmad R, Esnaashari, Omid, Ramzi, Mani, Taghizadeh, Ali, Najafi, Safa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Research Institute of Tuberculosis and Lung Disease 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210576/
https://www.ncbi.nlm.nih.gov/pubmed/32411265
_version_ 1783531302181404672
author Sharif-Kashani, Babak
Ghanbari Motlagh, Ali
Mafi, Ahmad R
Esnaashari, Omid
Ramzi, Mani
Taghizadeh, Ali
Najafi, Safa
author_facet Sharif-Kashani, Babak
Ghanbari Motlagh, Ali
Mafi, Ahmad R
Esnaashari, Omid
Ramzi, Mani
Taghizadeh, Ali
Najafi, Safa
author_sort Sharif-Kashani, Babak
collection PubMed
description BACKGROUND: Venous thromboembolism (VTE) is one of the main causes of mortality in patients with cancer. This study was conducted to assess the incidence of deep vein thrombosis (DVT) in breast cancer patients receiving outpatient cancer therapy. MATERIALS AND METHODS: This multi-center prospective cohort study was conducted on patients with breast cancer, initiating an outpatient chemotherapy regimen in five medical centers in Iran. Eligible patients were enrolled in the study consecutively between January 2013 and January 2015. The primary outcome was lower extremity DVT based on duplex/doppler ultrasonography two months after the first course of chemotherapy (visit 2) and after the end of the course (visit 3). All patients were followed-up from the onset of chemotherapy until the first occurrence of lower extremity DVT, death, or the end of the course. RESULTS: A total of 427 eligible breast cancer patients were recruited in the study, 403 of whom attended at least one follow-up visit. The mean (SD) duration of follow-up was 4 (1.3) months. During the follow-up, only one patient showed DVT on duplex/doppler ultrasonography in visit 2. Therefore, the two-month and overall cumulative incidence risk of DVT was 0.25% (95% CI: 0.00–0.74%). However, the mean D-dimer level showed no significant change (P>0.05). CONCLUSION: Our findings showed the low risk of DVT in breast cancer patients receiving outpatient cancer therapy.
format Online
Article
Text
id pubmed-7210576
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher National Research Institute of Tuberculosis and Lung Disease
record_format MEDLINE/PubMed
spelling pubmed-72105762020-05-14 The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran Sharif-Kashani, Babak Ghanbari Motlagh, Ali Mafi, Ahmad R Esnaashari, Omid Ramzi, Mani Taghizadeh, Ali Najafi, Safa Tanaffos Original Article BACKGROUND: Venous thromboembolism (VTE) is one of the main causes of mortality in patients with cancer. This study was conducted to assess the incidence of deep vein thrombosis (DVT) in breast cancer patients receiving outpatient cancer therapy. MATERIALS AND METHODS: This multi-center prospective cohort study was conducted on patients with breast cancer, initiating an outpatient chemotherapy regimen in five medical centers in Iran. Eligible patients were enrolled in the study consecutively between January 2013 and January 2015. The primary outcome was lower extremity DVT based on duplex/doppler ultrasonography two months after the first course of chemotherapy (visit 2) and after the end of the course (visit 3). All patients were followed-up from the onset of chemotherapy until the first occurrence of lower extremity DVT, death, or the end of the course. RESULTS: A total of 427 eligible breast cancer patients were recruited in the study, 403 of whom attended at least one follow-up visit. The mean (SD) duration of follow-up was 4 (1.3) months. During the follow-up, only one patient showed DVT on duplex/doppler ultrasonography in visit 2. Therefore, the two-month and overall cumulative incidence risk of DVT was 0.25% (95% CI: 0.00–0.74%). However, the mean D-dimer level showed no significant change (P>0.05). CONCLUSION: Our findings showed the low risk of DVT in breast cancer patients receiving outpatient cancer therapy. National Research Institute of Tuberculosis and Lung Disease 2019-03 /pmc/articles/PMC7210576/ /pubmed/32411265 Text en Copyright© 2019 National Research Institute of Tuberculosis and Lung Disease http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Sharif-Kashani, Babak
Ghanbari Motlagh, Ali
Mafi, Ahmad R
Esnaashari, Omid
Ramzi, Mani
Taghizadeh, Ali
Najafi, Safa
The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran
title The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran
title_full The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran
title_fullStr The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran
title_full_unstemmed The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran
title_short The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran
title_sort incidence of deep vein thrombosis in breast cancer patients receiving outpatient cancer therapy in iran
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210576/
https://www.ncbi.nlm.nih.gov/pubmed/32411265
work_keys_str_mv AT sharifkashanibabak theincidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran
AT ghanbarimotlaghali theincidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran
AT mafiahmadr theincidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran
AT esnaashariomid theincidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran
AT ramzimani theincidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran
AT taghizadehali theincidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran
AT najafisafa theincidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran
AT sharifkashanibabak incidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran
AT ghanbarimotlaghali incidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran
AT mafiahmadr incidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran
AT esnaashariomid incidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran
AT ramzimani incidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran
AT taghizadehali incidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran
AT najafisafa incidenceofdeepveinthrombosisinbreastcancerpatientsreceivingoutpatientcancertherapyiniran